Aspen Pharmacare Holdings Limited
http://www.aspenpharma.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aspen Pharmacare Holdings Limited
Aspen Says Reshaping Has Been ‘Painful’ But Is Over Now
Fresh from announcing the €642m ($762m) divestment of its Thrombosis business in Europe to Mylan, Aspen Pharmacare management walked investors through its full-year earnings, explaining in detail the company’s ambitions to focus on emerging markets.
Aspen Explains Logic Behind €642m Mylan Thrombosis Deal
Aspen Pharmacare last week announced the sale of its thrombosis business in Europe to Mylan for €642m ($762m). CEO Stephen Saad faced investors to detail the rationale for the US firm and what the planned transaction means for Aspen, including its material debt pile.
Upjohn To Divest Three In Australia To Complete On Viatris
Another regulatory approval for Mylan and Upjohn’s proposed combination into Viatris has been ticked off, with the Australian Competition and Consumer Commission saying it will not oppose the deal after Upjohn agreed to divestments to Aspen Pharmacare.
Mylan Strikes €642m Deal For Aspen’s Thrombosis Business In Europe
With Mylan continuing to count down the days until its merger with Pfizer’s Upjohn completes, the US firm has struck a deal to acquire Aspen Pharmacare’s thrombosis business in Europe, bolstering what is already a $4bn operation.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
- Other Names / Subsidiaries
-
- Aspen Global Incorporated (AGI)
- Aspen Japan K.K.